US protection ending in 2035: Nutrition and metabolism
As of the edition of 20 October 2026, 20 drugs have US protection that ends in 2035 in nutrition and metabolism; 10 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
20 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Bictegravir | Ends 2035 (patent) | Marketed | Gilead Sciences | 0 | |
| Cipaglucosidase alfa | Ends 2035 (computed from the first US licence) | Marketed | Amicus Therapeutics | IGF2R | 1 |
| Donislecel | Ends 2035 (computed from the first US licence) | Marketed | CellTrans | 0 | |
| Elranatamab | Ends 2035 (computed from the first US licence) | Marketed | Pfizer | CD3E, TNFRSF17 | 1 |
| Exagamglogene autotemcel | Ends 2035 (computed from the first US licence) | Marketed | Vertex | BCL11A | 1 |
| Ferric maltol | Ends 2035 (patent) | Marketed | Shield Tx | 0 | |
| Finerenone | Ends 2035 (patent) | Marketed | Bayer | NR3C2 | 0 |
| Florquinitau | Ends 2035 (patent) | Marketed | CERVEAU TECHNOLOGIES INC A LANTHEUS CO | MAPT | 0 |
| Mirikizumab | Ends 2035 (computed from the first US licence) | Marketed | Eli Lilly | IL23A | 1 |
| Pegunigalsidase alfa | Ends 2035 (computed from the first US licence) | Marketed | Chiesi Farmaceutici | 0 | |
| Perflutren | Ends 2035 (patent) | Marketed | Lantheus Medical Imaging | 0 | |
| Remdesivir | Ends 2035 (patent) | Marketed | Gilead Sciences | 0 | |
| Selinexor | Ends 2035 (patent) | Marketed | Karyopharm Therapeutics | XPO1 | 2 |
| Sodium zirconium cyclosilicate | Ends 2035 (patent) | Marketed | AstraZeneca | 0 | |
| Tafamidis | Ends 2035 (patent) | Marketed | Pfizer | TTR | 1 |
| Talquetamab | Ends 2035 (computed from the first US licence) | Marketed | Johnson & Johnson | CD3D, CD3E, CD3G | 1 |
| Tofersen | Ends 2035 (patent) | Marketed | Biogen | SOD1 | 1 |
| Toripalimab | Ends 2035 (computed from the first US licence) | Marketed | Coherus Oncology | PDCD1 | 2 |
| Velmanase alfa | Ends 2035 (computed from the first US licence) | Marketed | Chiesi Farmaceutici | 0 | |
| Vosoritide | Ends 2035 (patent) | Marketed | Amicus Therapeutics | NPR2 | 1 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2035 in nutrition and metabolism
In the product10 of these 20 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.